HRD
1 EU-approved indication of 1 drug needs a HRD result, in 1 tumour type, most of them in ovarian cancer.
Approved indications1
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| Ovarian cancer1 | ||||
Lynparza | HRD-positive (BRCA1/2 mutation and/or genomic instability) | + bevacizumab | Maint. advanced | High-grade only; In complete or partial response following completion of first-line platinum-based chemotherapy in combination with bevacizumab |
HRD by tumour
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Olaparib (Lynparza)
maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).